Increased T-Allele Frequency of 677 C > T Polymorphism in the Methylenetetrahydrofolate Reductase Gene in Differentiated Thyroid Carcinoma

Basit Öğe Kaydı
dc.contributor.authorOzdemir, Semra
dc.contributor.authorSılan, Fatma
dc.contributor.authorHasbek, Zekiye
dc.contributor.authorUludağ, Ahmet
dc.contributor.authorAtik, Sinem
dc.contributor.authorErselcan, Taner
dc.contributor.authorÖzdemir, Öztürk
dc.date.accessioned2025-01-27T20:25:11Z
dc.date.available2025-01-27T20:25:11Z
dc.date.issued2012
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractBackground: Epigenetic alterations in the global DNA methylation status may be associated with an increased risk of some cancer types in humans. The methylenetetrahydrofolate reductase (MTHFR) gene is involved in folic acid metabolism and plays an essential role in inherited DNA methylation profiles. The common 677 C > T and 1298 A > C polymorphisms in the MTHFR gene cause the production of a thermolabile enzyme with reduced function and, eventually, genomic DNA hypomethylation. The current preliminary study was designed to determine the association between germ-line polymorphism in the MTHFR gene and differentiated thyroid carcinoma (DTC). Methods: In the current case-control study of 60 thyroid carcinomas (TC); 45 papillary TC, 9 follicular TC, and 6 DTC of an uncertain malignant potential were examined. Genomic DNA was extracted from peripheral blood with EDTA, genotyped by a multiplex real-time polymerase chain reaction. Results: An elevated 2.33-fold risk was observed for DTC in individuals with the 677TT genotype when compared with the control group (odds ratio [OR]: 1.92, 95% confidence interval [CI]: 1.03-3.58). Current DTC patients showed similar results as a control group for the 1298 A > C allele. No significant risk was detected for the homozygous 1298CC genotype (CC vs. AA or AC) (OR: 1.30, 95% CI: 0.73-2.29). Conclusion: The current results are supportive of the hypothesis that the homozygous MTHFR 677TT genotype increases the risk factor of developing thyroid cancer, and further large-scale studies are needed to validate this association.
dc.identifier.doi10.1089/gtmb.2011.0347
dc.identifier.endpage784
dc.identifier.issn1945-0265
dc.identifier.issn1945-0257
dc.identifier.issue7
dc.identifier.pmid22536880
dc.identifier.scopus2-s2.0-84863954167
dc.identifier.scopusqualityQ3
dc.identifier.startpage780
dc.identifier.urihttps://doi.org/10.1089/gtmb.2011.0347
dc.identifier.urihttps://hdl.handle.net/20.500.12428/22455
dc.identifier.volume16
dc.identifier.wosWOS:000306475100024
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMary Ann Liebert, Inc
dc.relation.ispartofGenetic Testing and Molecular Biomarkers
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectDna Methylation
dc.subjectCancer-Risk
dc.subjectMthfr C677t
dc.subjectOral-Cancer
dc.subjectFolate
dc.subjectExpression
dc.subjectEsophageal
dc.subjectMetastasis
dc.subjectMutation
dc.subjectSmoking
dc.titleIncreased T-Allele Frequency of 677 C > T Polymorphism in the Methylenetetrahydrofolate Reductase Gene in Differentiated Thyroid Carcinoma
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu